Affiliation:
1. Clinical and Environmental Microbiology Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
Abstract
ABSTRACT
We compared the results obtained with six commercial MIC test systems (Etest, MicroScan, Phoenix, Sensititre, Vitek Legacy, and Vitek 2 systems) and three reference methods (agar dilution, disk diffusion, and vancomycin [VA] agar screen [VScr]) with the results obtained by the Clinical and Laboratory Standards Institute broth microdilution (BMD) reference method for the detection of VA-intermediate
Staphylococcus aureus
(VISA). A total of 129
S. aureus
isolates (VA MICs by previous BMD tests, ≤1 μg/ml [
n
= 60 strains], 2 μg/ml [
n
= 24], 4 μg/ml [
n
= 36], or 8 μg/ml [
n
= 9]) were selected from the Centers for Disease Control and Prevention strain collection. The results of BMD with Difco Mueller-Hinton broth were used as the standard for data analysis. Essential agreement (percent ±1 dilution) ranged from 98 to 100% for all methods except the method with the Vitek Legacy system, for which it was 90.6%. Of the six commercial MIC systems tested, the Sensititre, Vitek Legacy, and Vitek 2 systems tended to categorize VISA strains as susceptible (i.e., they undercalled resistance); the MicroScan and Phoenix systems and Etest tended to categorize susceptible strains as VISA; and the Vitek Legacy system tended to categorize VISA strains as resistant (i.e., it overcalled resistance). Disk diffusion categorized all VISA strains as susceptible. No susceptible strains (MICs ≤ 2 μg/ml) grew on the VScr, but all strains for which the VA MICs were 8 μg/ml grew on the VScr. Only 12 (33.3%) strains for which the VA MICs were 4 μg/ml grew on VScr. The differentiation of isolates for which the VA MICs were 2 or 4 μg/ml was difficult for most systems and methods, including the reference methods.
Publisher
American Society for Microbiology
Reference10 articles.
1. Appelbaum, P. C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents30:398-408.
2. CLSI document M7-A7. 2006
3. CLSI document M2-A9. 2006
4. CLSI document M100-S19 2009
5. Jones, R., M. Stilwell, H. Sader, T. Fritsche, and B. P. Goldstein. 2006. Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis.53:149-153.
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献